See more : Killam Apartment REIT (KMMPF) Income Statement Analysis – Financial Results
Complete financial analysis of VectivBio Holding AG (VECT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of VectivBio Holding AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Daohe Global Group Limited (0915.HK) Income Statement Analysis – Financial Results
- UHF Logistics Group, Inc. (RGLG) Income Statement Analysis – Financial Results
- Nektar Therapeutics (NKTR) Income Statement Analysis – Financial Results
- Ocular Therapeutix, Inc. (OCUL) Income Statement Analysis – Financial Results
- Aditya Birla Sun Life AMC Limited (ABSLAMC.BO) Income Statement Analysis – Financial Results
VectivBio Holding AG (VECT)
About VectivBio Holding AG
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 27.34M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 27.34M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 73.95M | 50.18M | 43.04M | 15.98M |
| General & Administrative | 33.91M | 35.81M | 14.02M | 8.23M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.91M | 35.81M | 14.02M | 8.23M |
| Other Expenses | 0.00 | 729.00K | 207.00K | 102.00K |
| Operating Expenses | 107.87M | 86.72M | 57.26M | 24.32M |
| Cost & Expenses | 107.87M | 86.72M | 57.26M | 24.32M |
| Interest Income | 676.00K | 0.00 | 1.00K | 15.00K |
| Interest Expense | 3.16M | 36.00K | 554.00K | 50.00K |
| Depreciation & Amortization | 676.00K | 303.00K | -293.00K | 167.00K |
| EBITDA | -79.85M | -86.41M | -57.55M | -24.15M |
| EBITDA Ratio | -292.04% | 0.00% | 0.00% | 0.00% |
| Operating Income | -80.52M | -86.72M | -57.26M | -24.32M |
| Operating Income Ratio | -294.52% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.10M | -293.00K | -2.68M | 834.00K |
| Income Before Tax | -93.63M | -86.95M | -59.94M | -23.48M |
| Income Before Tax Ratio | -342.45% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 107.00K | 64.00K | 554.00K | 50.00K |
| Net Income | -93.74M | -87.01M | -60.50M | -23.53M |
| Net Income Ratio | -342.84% | 0.00% | 0.00% | 0.00% |
| EPS | -2.12 | -3.23 | -6.30 | -1.01 |
| EPS Diluted | -2.12 | -3.23 | -6.30 | -1.01 |
| Weighted Avg Shares Out | 44.13M | 26.96M | 9.60M | 23.35M |
| Weighted Avg Shares Out (Dil) | 44.13M | 26.96M | 9.60M | 23.35M |
VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary
VectivBio Announces Results of Extraordinary General Meeting
VectivBio to Acquire Comet Therapeutics and Host R&D Day
VectivBio Publishes Invitation to the Extraordinary General Meeting
VectivBio Nominates Paul R. Carter and Murray W.
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
VectivBio Announces First Patient Dosed in Metabolic Balance Study of Apraglutide in Colon-in-Continuity Patients with Short Bowel Syndrome with Intestinal Failure
VectivBio Appoints Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
CORRECTION – VectivBio Announces Closing of $146.6 Million Initial Public Offering
VectivBio Announces Closing of $146.6 Million Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports